KR101360526B1 - 개선된 약력학적 특성을 갖는 약물 제형 - Google Patents

개선된 약력학적 특성을 갖는 약물 제형 Download PDF

Info

Publication number
KR101360526B1
KR101360526B1 KR1020077022210A KR20077022210A KR101360526B1 KR 101360526 B1 KR101360526 B1 KR 101360526B1 KR 1020077022210 A KR1020077022210 A KR 1020077022210A KR 20077022210 A KR20077022210 A KR 20077022210A KR 101360526 B1 KR101360526 B1 KR 101360526B1
Authority
KR
South Korea
Prior art keywords
vardenafil
drug formulation
sugar alcohol
drug
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020077022210A
Other languages
English (en)
Korean (ko)
Other versions
KR20070110109A (ko
Inventor
페터 세르노
롤란트 하이니히
케르스틴 파울리
유타카 하야우치
Original Assignee
바이엘 인텔렉쳐 프로퍼티 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36264023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101360526(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 인텔렉쳐 프로퍼티 게엠베하 filed Critical 바이엘 인텔렉쳐 프로퍼티 게엠베하
Publication of KR20070110109A publication Critical patent/KR20070110109A/ko
Application granted granted Critical
Publication of KR101360526B1 publication Critical patent/KR101360526B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020077022210A 2005-03-01 2006-02-16 개선된 약력학적 특성을 갖는 약물 제형 Active KR101360526B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005009240.3 2005-03-01
DE102005009240A DE102005009240A1 (de) 2005-03-01 2005-03-01 Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
PCT/EP2006/001393 WO2006092207A1 (de) 2005-03-01 2006-02-16 Arzneiformen mit verbesserten pharmakokinetischen eigenschaften

Publications (2)

Publication Number Publication Date
KR20070110109A KR20070110109A (ko) 2007-11-15
KR101360526B1 true KR101360526B1 (ko) 2014-02-21

Family

ID=36264023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077022210A Active KR101360526B1 (ko) 2005-03-01 2006-02-16 개선된 약력학적 특성을 갖는 약물 제형

Country Status (38)

Country Link
US (2) US8613950B2 (enExample)
EP (2) EP2377523A1 (enExample)
JP (1) JP5122984B2 (enExample)
KR (1) KR101360526B1 (enExample)
CN (2) CN102198140B (enExample)
AR (2) AR053552A1 (enExample)
AT (1) ATE552828T1 (enExample)
AU (1) AU2006220100B2 (enExample)
BR (1) BRPI0609375A2 (enExample)
CA (1) CA2599617C (enExample)
CR (2) CR9339A (enExample)
CY (1) CY1112874T1 (enExample)
DE (1) DE102005009240A1 (enExample)
DK (1) DK1858490T3 (enExample)
DO (1) DOP2006000049A (enExample)
ES (1) ES2384109T3 (enExample)
GT (1) GT200600097A (enExample)
HN (1) HN2006009000A (enExample)
HR (1) HRP20120545T1 (enExample)
IL (2) IL185552A (enExample)
MA (1) MA29376B1 (enExample)
MX (1) MX2007010527A (enExample)
MY (2) MY177386A (enExample)
NO (2) NO332368B1 (enExample)
NZ (1) NZ561004A (enExample)
PE (2) PE20061015A1 (enExample)
PL (1) PL1858490T3 (enExample)
PT (1) PT1858490E (enExample)
RS (1) RS52374B (enExample)
RU (2) RU2423970C2 (enExample)
SG (1) SG160330A1 (enExample)
SI (1) SI1858490T1 (enExample)
TN (1) TNSN07336A1 (enExample)
TW (1) TWI387465B (enExample)
UA (1) UA93200C2 (enExample)
UY (1) UY29395A1 (enExample)
WO (1) WO2006092207A1 (enExample)
ZA (1) ZA200707320B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
CN102458475B (zh) 2009-05-20 2016-03-30 大日本住友制药株式会社 压制包衣的口腔崩解片
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
CN103372014B (zh) * 2012-04-26 2015-10-21 齐鲁制药有限公司 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法
CN102727455B (zh) * 2012-07-03 2016-06-29 北京科信必成医药科技发展有限公司 一种他达那非口腔崩解片及其制备方法
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN110193015A (zh) * 2018-02-27 2019-09-03 广州朗圣药业有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
CN108272765B (zh) * 2018-04-26 2021-02-02 江西杏林白马药业股份有限公司 含盐酸伐地那非的药物组合物、口崩片及其制备、应用
WO2019211159A1 (en) 2018-05-02 2019-11-07 Ferring B.V. Improved pharmaceutical formulations
CN110840851A (zh) * 2019-08-16 2020-02-28 天津仁卫生物医药科技有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
IT201900020350A1 (it) 2019-11-05 2021-05-05 Alpex Pharma Sa Formulazione orodispersibile di vardenafil
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
AU2021280285A1 (en) * 2020-05-26 2023-02-02 Strategic Drug Solutions, Inc. Formulations and methods for treating erectile dysfunction
CN114848603B (zh) * 2022-04-25 2023-12-12 湖北菲瑞生物药业有限公司 一种伐地那非冻干闪释片及其制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2492747A1 (en) * 2002-07-16 2004-01-22 Bayer Healthcare Ag Medicaments containing vardenafil hydrochloride trihydrate
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040202715A1 (en) * 1998-10-05 2004-10-14 Eisai Co., Ltd. Intraoral quickly disintegrating tablets

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
GB790762A (en) 1953-08-28 1958-02-19 Arthur Poole A hydrate of lignocaine hydrochloride and process for making it
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (enExample) * 1963-01-16
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
EP0054132B1 (de) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
ES2058527T3 (es) * 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US4939544A (en) * 1989-11-01 1990-07-03 Eastman Kodak Company Mask for radiation emitting panel
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
DK0524180T3 (da) * 1990-04-11 1995-09-04 Upjohn Co Smagsmaskering af ibuprofen ved fluid bedovertrækning
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
CA2148260A1 (en) 1993-09-10 1995-03-16 Yasutaka Takase Quinazoline cpompounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DK1174431T3 (da) * 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
MXPA02006240A (es) * 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
AU5714601A (en) * 2000-04-19 2001-10-30 Univ Johns Hopkins Methods for prevention and treatment of gastrointestinal disorders
WO2002036126A1 (en) * 2000-10-30 2002-05-10 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
US20040152700A1 (en) * 2001-05-09 2004-08-05 Ulrich Niewohner Novel use of 2-phenyl-substituted imidazotriazinones
BR0205509A (pt) 2001-07-27 2003-06-24 Yamanouchi Pharma Co Ltd Composição compreendendo partìculas finas de liberação prolongada para comprimidos de rápida desintegração na cavidade bucal e método de fabricação da mesma
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
WO2004110411A2 (fr) 2003-06-06 2004-12-23 Ethypharm Comprime orodispersible multicouche
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
KR20070058381A (ko) 2004-04-27 2007-06-08 메디시노바, 인크. 염증성 질환 치료용 페녹시알킬카르복실 산 유도체
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006058250A2 (en) 2004-11-24 2006-06-01 Spi Pharma, Inc. Orally disintegrating compositions
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
MX2008000087A (es) 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
WO2007029376A1 (ja) 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. 口腔内速崩壊性錠剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202715A1 (en) * 1998-10-05 2004-10-14 Eisai Co., Ltd. Intraoral quickly disintegrating tablets
CA2492747A1 (en) * 2002-07-16 2004-01-22 Bayer Healthcare Ag Medicaments containing vardenafil hydrochloride trihydrate
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods

Also Published As

Publication number Publication date
CN102198140A (zh) 2011-09-28
KR20070110109A (ko) 2007-11-15
CN101141950B (zh) 2011-06-08
ES2384109T3 (es) 2012-06-29
JP2008531614A (ja) 2008-08-14
SI1858490T1 (sl) 2012-07-31
CY1112874T1 (el) 2016-04-13
NO20074848L (no) 2007-09-27
MX2007010527A (es) 2007-11-08
AU2006220100B2 (en) 2011-08-18
PE20061015A1 (es) 2006-10-20
CA2599617C (en) 2012-01-10
US8613950B2 (en) 2013-12-24
HN2006009000A (es) 2010-08-05
MY177386A (en) 2020-09-14
DOP2006000049A (es) 2006-10-31
WO2006092207A1 (de) 2006-09-08
TW200640503A (en) 2006-12-01
NO332368B1 (no) 2012-09-03
PL1858490T3 (pl) 2012-09-28
RU2011111106A (ru) 2012-09-27
UY29395A1 (es) 2006-10-02
NO20120203L (no) 2007-09-27
NO344546B1 (no) 2020-01-27
ZA200707320B (en) 2009-08-26
HK1118457A1 (en) 2009-02-13
CR9339A (es) 2007-12-17
JP5122984B2 (ja) 2013-01-16
TNSN07336A1 (en) 2008-12-31
AU2006220100A1 (en) 2006-09-08
SG160330A1 (en) 2010-04-29
UA93200C2 (ru) 2011-01-25
IL246548A0 (en) 2016-08-31
RU2423970C2 (ru) 2011-07-20
RS52374B (sr) 2012-12-31
IL185552A (en) 2017-06-29
CA2599617A1 (en) 2006-09-08
EP1858490B1 (de) 2012-04-11
US20080249096A1 (en) 2008-10-09
MY148698A (en) 2013-05-31
CN102198140B (zh) 2016-06-08
CN101141950A (zh) 2008-03-12
AR111572A2 (es) 2019-07-31
DE102005009240A1 (de) 2006-09-07
RU2481110C2 (ru) 2013-05-10
EP1858490A1 (de) 2007-11-28
EP2377523A1 (de) 2011-10-19
TWI387465B (zh) 2013-03-01
IL185552A0 (en) 2008-01-06
BRPI0609375A2 (pt) 2010-03-30
PT1858490E (pt) 2012-06-19
DK1858490T3 (da) 2012-07-23
ATE552828T1 (de) 2012-04-15
NZ561004A (en) 2010-12-24
US20140186444A1 (en) 2014-07-03
AR053552A1 (es) 2007-05-09
MA29376B1 (fr) 2008-04-01
HRP20120545T1 (hr) 2012-07-31
CR20130381A (es) 2013-09-12
PE20100740A1 (es) 2010-10-28
GT200600097A (es) 2006-11-13
RU2007135982A (ru) 2009-04-10

Similar Documents

Publication Publication Date Title
RU2481110C2 (ru) Лекарственные формы с улучшенными фармакокинетическими свойствами
US8048449B2 (en) Mouth dissolving pharmaceutical composition and process for preparing the same
US20090263476A1 (en) Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US20070082048A1 (en) Sleep aid formulations
EP1652524A1 (en) Dry syrup containing loratadine
EP2563340A2 (en) Water soluble pharmaceutical composition
KR20100086140A (ko) 몬테루카스트를 활성성분으로 함유하는 구강 내 속붕해정 조성물 및 그 제조방법
US20110257159A1 (en) Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
Amrutkar et al. Design and evaluation of taste masked chewable dispersible tablet of lamotrigine by melt granulation
US20140235656A1 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
EP4183390A1 (en) An orodispersible pharmaceutical dosage form of edoxaban
WO2013098399A1 (en) Mozavaptan formulations
AU2011250768A1 (en) Pharmaceutical forms with improved pharmacokinetic properties
EP4436553A1 (en) An orodispersible pharmaceutical dosage form of edoxaban
US20250339366A1 (en) An orodispersible tablet of rivaroxaban
HK1160406B (en) Pharmaceutical forms with improved pharmacokinetic properties
HK1160406A (en) Pharmaceutical forms with improved pharmacokinetic properties
TW202102206A (zh) 口腔內崩散錠的製造方法及口腔內崩散錠
HK1118457B (en) Pharmaceutical forms with improved pharmacokinetic properties
WO2013117793A1 (es) Composición farmacéutica sólida de cilostazol

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070928

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20090825

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130122

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130617

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20131129

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140203

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170201

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170201

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180201

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180201

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190129

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190129

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20200129

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20200129

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210127

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220127

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230130

Start annual number: 10

End annual number: 10